BioNTech SE (BNTX) EBT Margin (2018 - 2025)
BioNTech SE (BNTX) posted EBT Margin of 25.06% for Q4 2025, down 1641.08% sequentially from 1.63% in Q3 2025, and down 2507.0% YoY from 1.04% in Q4 2024.
BioNTech SE (BNTX) EBT Margin (2018 - 2025) Analysis & Trends
BioNTech SE has reported EBT Margin for 8 years, with the latest figure at 25.06% in Q4 2025.
- Quarterly EBT Margin fell 2507.0% year-over-year to 25.06% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 34.95% (down 3493.0% YoY) and the FY2025 annual result came in at 36.61%, down 1198.0% from the prior year.
- EBT Margin declined to 25.06% in Q4 2025 per BNTX's latest filing, from 1.63% in the prior quarter.
- Over five years, EBT Margin peaked at 85.2% in Q4 2021 and troughed at 626.11% in Q2 2024.
- A 5-year average of 35.9% and a median of 35.12% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin slumped 38031 bps in 2024, then surged 47170 bps in 2025.
- Over 5 years, EBT Margin stood at 85.2% in 2021, then dropped by 13 bps to 74.16% in 2022, then tumbled by 40 bps to 44.84% in 2023, then slumped by 100 bps to 0.01% in 2024, then sank by 274668 bps to 25.06% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 25.06%, 1.63%, and 154.41% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -25.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25.06% |
| Sep 30, 2025 | 1.63% |
| Jun 30, 2025 | -154.41% |
| Mar 31, 2025 | -243.65% |
| Dec 31, 2024 | 25.31% |
| Sep 30, 2024 | 12.75% |
| Jun 30, 2024 | -626.11% |
| Mar 31, 2024 | -176.87% |
| Dec 31, 2023 | 44.84% |
| Sep 30, 2023 | 25.40% |
| Jun 30, 2023 | -245.80% |
| Mar 31, 2023 | 55.42% |
| Dec 31, 2022 | 74.16% |
| Sep 30, 2022 | 70.61% |
| Jun 30, 2022 | 72.56% |
| Mar 31, 2022 | 78.72% |
| Dec 31, 2021 | 85.20% |
| Sep 30, 2021 | 76.67% |
| Jun 30, 2021 | 75.78% |
| Mar 31, 2021 | 80.17% |